Fenimac outlines $160 million in annual expense cuts as it expects adjusted ROE in the fourth quarter of 2026 to remain close to current levels.
Fenimac outlines $160 million in annual expense cuts as it expects adjusted ROE in the fourth quarter of 2026 to remain close to current levels.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in